$349.91
Value $318B
UNH and VRTX stock compared: price, dividend, valuation and results, from SEC filings.
$349.91
Value $318B
$536.45
Value $136B
UnitedHealth (UNH) has a market value of $318B and Vertex Pharmaceuticals (VRTX) $136B. Over the last year, with dividends, UNH moved +12.1% and VRTX +23.6%. The P/E is 20.0 for UNH and 34.3 for VRTX. Dividend yield: UNH 2.59%, VRTX none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
UNH$318B
VRTX$136B
UNH is 2.3 times VRTX
Revenue, 12 months
UNH$450B
VRTX$13.0B
UNH is 35 times VRTX
Net income, 12 months
UNH$15.9B
VRTX$4.0B
UNH is 4.0 times VRTX
Operating margin
UNH5.3%
VRTX33.2%
27.9 points apart
ROIC
UNH11.3%
VRTX17.9%
6.6 points apart
P/E
UNH20.0
VRTX34.3
VRTX is 1.7 times UNH
Dividend yield
UNH2.6%
VRTX0.0%
2.6 points apart
5-year return
UNH-14.7%
VRTX+185.0%
199.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
UNH-14.7%
VRTX+185.0%
| Period | UNHWith dividends | VRTXWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +12.1%Price +9.2% | +23.6%Price +23.6% |
| 3 years since November 17, 2023 | -30.5%-11.4% a yearPrice -34.8% | +53.1%+15.2% a yearPrice +53.1% |
| 5 years since November 17, 2021 | -14.7%-3.1% a yearPrice -22.1% | +185.0%+23.3% a yearPrice +185.0% |
| 10 years since November 18, 2016 | +176.5%+10.7% a yearPrice +134.1% | +499.8%+19.6% a yearPrice +499.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
UNHUnitedHealthVRTXVertex Pharmaceuticals
| Price | $349.91 | $536.45 |
|---|---|---|
| Market value | $318B | $136B |
| Enterprise value (EV) | $363B | $134B |
| P/E | 20.0 | 34.3 |
| P/E, 5-year median | 25.0 | 26.8 |
| P/B | 3.1 | 6.5 |
| EV/EBIT | 15.2 | 31.2 |
| Free cash flow yield | 7.2% | 2.4% |
| Revenue, 12 months | $450B | $13.0B |
|---|---|---|
| Net income, 12 months | $15.9B | $4.0B |
| Free cash flow, 12 months | $22.8B | $3.2B |
| Earnings per share, 12 months | $17.52 | $15.53 |
| Revenue growth, year on year | 11.8% | 8.9% |
| Revenue growth a year, past | +11.7%over 5 years | +14.1%over 5 years |
| EPS growth a year, past | -3.8%over 5 years | +8.3%over 5 years |
| Gross margin | 88.3% | 85.5% |
|---|---|---|
| Operating margin | 5.3% | 33.2% |
| Net margin | 3.5% | 30.7% |
| ROIC | 11.3% | 17.9% |
| ROE | 15.5% | 20.6% |
| Cash | $28.5B | $6.3B |
|---|---|---|
| Total debt | $74.3B | $6.5B |
| Net debt / EBITDA | 1.6 | -0.4 |
| Interest cover | 6.2× | 94.4× |
| Dividend yield | 2.6% | – |
|---|---|---|
| Dividend per share, 12 months | $9.06 | – |
| Dividend growth a year, past | +12.6%over 5 years | – |
| Buyback yield | 1.8% | 1.5% |
| Shareholder yield | 4.3% | 1.5% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($318B) is about 2.3 times Vertex Pharmaceuticals ($136B), at today's prices.
Since November 18, 2016, UNH's price moved +134.1% and VRTX's +499.8%. With dividends: UNH +176.5% (+10.7% a year), VRTX +499.8% (+19.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.59% for UnitedHealth and none for Vertex Pharmaceuticals. Over the last twelve months they paid $9.06 and – per share.
At today's price, the P/E is 20.0 for UNH and 34.3 for VRTX. The median of the last five years was 25.0 and 26.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 3.5% for UnitedHealth and 30.7% for Vertex Pharmaceuticals, and the operating margin 5.3% and 33.2%. Revenue was $450B and $13.0B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.